Dearbhaile O'Hanlon  © ECCO

D-ECCO is committed to promoting the essential role of dietitians within the Inflammatory Bowel Disease Multidisciplinary Team (IBD MDT). Specialist IBD dietitians in IBD units are integral to the MDT, but not all IBD units have a specialist dietitian. Dietetic services and clinical roles are likely to differ slightly from country to country, but the core roles will remain the same. The European Federation of the Associations of Dietitians (EFAD) has adopted the International Congress of Dietetic Associations (ICDA) definition of the role of the dietitian: “A person with a qualification in Nutrition & Dietetics recognized by national authority(s). The dietitian applies the science of nutrition to the feeding and education of groups of people and individuals in health and disease.”

Ana Ibarra © ECCO

Everyone would agree that IBD specialist nurses do an incredible amount of work to help patients with Inflammatory Bowel Disease (IBD). Over the years we have learnt that patients with IBD require access to our services when they need them, rather than simply at their next scheduled appointment in the clinic. Patients also think that one of the most important things that IBD specialist nurses can provide is high-quality advice and information, especially when they feel unwell.

Petra Hartmann  © ECCO

ECCO offers Research Grants for IBD Nurses in order to promote innovative scientific research in the area of IBD Nursing across Europe. The N-ECCO Research Grant provides nurses with a great opportunity to gain economic support, and this year a total of EUR 20,000.- will be awarded.

The N-ECCO Research Grant aims to enhance the opportunities for IBD Nurses to become involved in international research projects across Europe. The goals are to enable IBD Nurses less experienced in research to engage in research activities, with mentoring by senior researchers; to promote IBD-related basic and clinical research; and to foster interaction and productive collaboration among European research groups working in the IBD field. 

Tim Raine  © ECCO

At the ECCO Congress 2020, 15 representatives from 11 countries gathered to discuss the ECCO GuiCom Topical Review on Refractory IBD. This project is being led by Tim Raine (United Kingdom) and Garret Cullen (Ireland). The aim of the project is to bring together evidence and recommendations on how to approach the patient with active Crohn’s Disease (CD) or Ulcerative Colitis (UC) who has not responded to all licensed treatment options.

Pascal Juillerat  © ECCO

Dear ECCO Members,

I would like to thank my predecessor, Peter Irving, for championing the role of ECCO e-Learning Ambassador and now passing the baton on to me. I am honoured to take on this responsibility and thrilled to be able to reach out to you with the latest news regarding the e-CCO Learning Platform. 

Naila Arebi  © ECCO

"Out with the old, in with the new"

Change is the cornerstone of the innovation that drives science forward. Of many expressions that capture change, ‘out with the old, in with the new’ expresses well what occurs when the composition of committees alters. As members step down and new members take their place, fresh ideas and different perspectives are heard, leading to renewed enthusiasm that will drive the agenda for the future. Against this backdrop, EpiCom welcomes Sophie Restellini while bidding a sad farewell to Marieke Pierik.

Myrthe Jongsma © Myrthe Jongsma

Top-down infliximab is superior to step-up in children with moderate-to-severe Crohn’s Disease

In newly diagnosed paediatric patients with Crohn’s Disease (CD), rapid disease control is desirable, but this outcome is not always achieved with current treatment strategies [1]. Infliximab has been proven to be highly effective in paediatric CD patients [2], but its primary use is reserved for patients with perianal disease or a predicted severe disease course [3]. We investigated whether starting top-down infliximab immediately after diagnosis is more effective than conventional step-up treatment in achieving and sustaining remission in children with moderate to severe CD.

Toer Stevens © Toer Stevens

Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s Disease:  Long-term follow-up of the LIR!C trial

The LIR!C trial was a randomised controlled trial conducted between 2008 and 2015. It included 143 patients with non-stricturing ileocaecal Crohn’s Disease (<40 cm) who failed conventional treatment.

Michael Scharl © ECCO

Marc Ferrante © ECCO

Sebastian Zeissig © ECCO

Similarities and differences in the pathogenesis of immune-mediated inflammatory disorders 

This year’s SciCom Workshop focussed on common and distinct pathways in immune-mediated disorders and the application of this knowledge for early disease recognition and interception as well as for the treatment of established disease.

Sebastian Zeissig  © ECCO

During the ECCO’20 Vienna Congress, the Scientific Committee cordially welcomed Konstantinos Papamichail and Yves Panis as new members of SciCom.

Konstantinos Papamichail has been an ECCO Member since 2007 and has participated in several ECCO Activities, including the 7th ECCO Advanced Course and the ECCO ‘EXIT strategies’ Topical Review. He is a reviewer of the ECCO Grants and also a member of the editorial board of JCC. After completing his PhD in Pharmacology and his GI Fellowship in Greece, Kostas joined the Leuven IBD group as a post-doctoral researcher for 3 years and was also a recipient of an ECCO Fellowship. For the last 5 years he has been working at the Beth Israel Deaconess Medical Center in Boston, where his research has focussed on the role of therapeutic drug monitoring of biologics in IBD. He is the author of numerous publications and his goal is to stimulate scientific interactions in the ECCO Community and beyond and to interact with the other ECCO Committees in order to promote and support national and international IBD research efforts towards the better care of patients with IBD.